Paul‐peter Tak - Pharma

Author Information

Dr. Paul Peter Tak is affiliated with the Department of Clinical Immunology & Rheumatology at the Academic Medical Centre, Amsterdam University Medical Centre, Amsterdam, Netherlands. With a robust academic and clinical background, Dr. Tak has made significant contributions to the fields of immunology and rheumatology.

Research Contributions

Dr. Paul Peter Tak has contributed extensively to the understanding and treatment of autoimmune and inflammatory diseases. His research has focused on the molecular and cellular mechanisms underlying conditions such as rheumatoid arthritis and psoriatic arthritis. Notably, his recent work has explored the impact of treatments like Adalimumab and novel insights into immune-mediated inflammation across various diseases. Dr. Tak's studies have not only advanced scientific knowledge but have also had significant clinical implications, particularly in developing individualized treatment strategies.

Aliases

Dr. Paul Peter Tak is also known by several aliases, including P.-p. Tak, P. Tak, Paul-p. Tak, Paul P. Tak, Paul-peter Tak, and P Peter Tak, among others.

Publication and Citation Metrics

Total Papers	763
Total Citations	61,422
h-index	116
Recent Papers (2021-2022)	Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis (2022) Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models (2022) Increased Frequency of CD4+ Follicular Helper T and CD8+ Follicular T Cells in Human Lymph Node Biopsies during the Earliest Stages of Rheumatoid Arthritis (2022) Synovial Gene Signatures Associated with the Development of Rheumatoid Arthritis in At Risk Individuals: a Prospective Study (2021) Detection of viral antigen and immune activation after intra-tumor injection of CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma (2021) A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis (2021) Immune-mediated inflammation across disease boundaries: breaking down research silos (2021) Novel Insights Into Rheumatoid Arthritis Through Characterization of Concordant Changes in DNA Methylation and Gene Expression in Synovial Biopsies of Patients With Differing Numbers of Swollen Joints (2021) CTIM-13. PHASE 1 CLINICAL TRIAL OF ONCOLYTIC VIRAL IMMUNOTHERAPY WITH CAN-2409 + VALACYCLOVIR IN COMBINATION WITH NIVOLUMAB AND STANDARD OF CARE (SOC) IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG) (2021) Towards Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: a Pharmacogenomics-driven Machine Learning Approach (2021)